Antibody–drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target?
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody–drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target?
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume -, Issue -, Pages 1-4
Publisher
Informa UK Limited
Online
2023-10-28
DOI
10.1080/14712598.2023.2277915
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.
- (2023) John H Strickler et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
- (2023) Kanwal Pratap Singh Raghav et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
- (2023) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
- (2023) Fabrice André et al. LANCET
- Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
- (2023) John H Strickler et al. LANCET ONCOLOGY
- Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
- (2023) Takayuki Yoshino et al. Nature Communications
- Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
- (2023) K. Jhaveri et al. ANNALS OF ONCOLOGY
- Resistance Mechanisms to HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma: A Systematic Review
- (2022) Dionne Blangé et al. CANCER TREATMENT REVIEWS
- Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?
- (2022) Chiara Corti et al. EUROPEAN JOURNAL OF CANCER
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era
- (2022) Maria Gion et al. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
- Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
- (2022) Sara A Hurvitz et al. LANCET
- Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
- (2021) Bob T. Li et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
- (2016) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- A note from history: Landmarks in history of cancer, Part 6
- (2013) Steven I. Hajdu et al. CANCER
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search